Cuts to the Bone: Orthopedic biotech slashes C-suite, overhauls entire pipeline
Cuts to the Bone: Orthopedic biotech slashes C-suite, overhauls entire [...]
ImmunoGen files ovarian cancer ADC with FDA, a week after scaring investors with iffy survival data
ImmunoGen files ovarian cancer ADC with FDA, a week after [...]
Biden seeks $2.1B funding boost for FDA, part of pan-agency pandemic preparedness plan
Biden seeks $2.1B funding boost for FDA, part of pan-agency [...]
Amylyx to answer for single-study ALS application at FDA advisory panel
Amylyx to answer for single-study ALS application at FDA advisory [...]
Another Biogen-Ionis collab hits the dust after phase 1 ALS flop
Another Biogen-Ionis collab hits the dust after phase 1 ALS [...]
Icosavax’s COVID-19 shot fails to deliver in early data, spurring debate about ‘fatal flaw’ in platform
Icosavax’s COVID-19 shot fails to deliver in early data, spurring [...]
89bio gains a little more confidence in NASH treatment with new hormone data
89bio gains a little more confidence in NASH treatment with [...]
AN2 upsizes IPO, teeing up bid to revitalize antibiotic let go by GSK and Pfizer
AN2 upsizes IPO, teeing up bid to revitalize antibiotic let [...]
MEI rocked as FDA request for randomized data on cancer drug ends hopes of accelerated approval
MEI rocked as FDA request for randomized data on cancer [...]
Chutes & Ladders—After 9 years at Merck, Roy Baynes follows Roger Perlmutter to Eikon
Chutes & Ladders—After 9 years at Merck, Roy Baynes follows [...]